Table 2.
Antitumor Best Response of DEB-TACE
| Antitumor Response | Number of Cases (Percent) | ||||
|---|---|---|---|---|---|
| Overall, n=27 | Child–Pugh | Up-to-7 | |||
| Child–Pugh A, n=19 | Child–Pugh B, n=8 | Up-to-7 In, n=15 | Up-to-7 Out, n=12 | ||
| CR | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| PR | 2 (7.4) | 1 (5.3) | 1 (12.5) | 0 (0) | 2 (16.7) |
| SD | 15 (55.6) | 9 (47.4) | 6 (75.0) | 10 (66.7) | 5 (41.7) |
| PD | 10 (37.0) | 9 (47.4) | 1 (12.5) | 5 (33.3) | 5 (41.7) |
Abbreviations: DEB-TACE, drug-eluting beads-transcatheter arterial chemoembolization; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.